Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Imraldi

- PMLiVE

Biogen and Eisai pull plug on Alzheimer’s drug

Further undermines amyloid-targeting approach

- PMLiVE

Roche, AbbVie hit by clinical hold for Venclexta in myeloma

Safety concerns could hit blockbuster expectations

Biogen Idec building

Biogen, Eisai cue up BAN2401 readout in Alzheimer’s in 2022

Also considering a trial in preclinical Alzheimer’s subjects

- PMLiVE

AbbVie and Boehringer’s psoriasis drug Skyrizi gets CHMP nod

Analysts say the drug could be a best-in-class candidate in the therapy area

Biogen Idec building

Biogen strikes $800m deal to buy gene therapy firm Nightstar

Will also acquire CHM candidate and a therapy for XLRP

Biogen Idec building

FDA starts review of Biogen’s Tecfidera follow-up for MS

It was initally submitted towards the end of 2018 but had been delayed by US gov shutdown

- PMLiVE

AbbVie enters BCMA race with Teneobio deal

Agreement includes option to acquire TeneoOne

- PMLiVE

Imbruvica and Gazyvo approved in first non-chemo CLL use

Further boost for blockbuster leukaemia drug

- PMLiVE

European biosimilars hit AbbVie’s Humira revenues in Q4

Strong full year growth, but M&A speculation will linger

- PMLiVE

NHS England sees off AbbVie’s Hep C legal challenge

Claims of unfair process dismissed by High Court

- PMLiVE

Biogen files Tecfidera follow-up in the US

Improved GI tolerability is major selling point

- PMLiVE

Biogen picks up another drug from wide-ranging Ionis alliance

Aims to follow success of Spinraza

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links